Analysts Lower Q1 2027 Earnings Estimates for Arcutis Biotherapeutics

1 report, 1 independent Updated Fri 00:00

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

HC Wainwright lowered its Q1 2027 earnings per share forecast for Arcutis Biotherapeutics to $0.07, down from a previous forecast of $0.08. This update comes after Arcutis Biotherapeutics reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.18 by $0.12. The company reported revenue of $143.92 million for the quarter.

From tickerreport.com

Why it matters

Some supportBrind's analysis of the reports

The updated earnings estimates from HC Wainwright, alongside prior rating changes from Jefferies Financial Group and Morgan Stanley, influence the market valuation of Arcutis Biotherapeutics. The consensus estimate for the company's current full year earnings is $0.43 per share.

From tickerreport.com

Who's involved

Jefferies Financial GroupIssued a 'buy' rating and $39.00 target price for Arcutis Biotherapeutics in October 2026.
Morgan StanleyRaised its price target on Arcutis Biotherapeutics to $38.00 in August 2026.
MarketBeatAggregates consensus estimates for Arcutis Biotherapeutics.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

MarketBeatSpeculative
MarketBeat might see changes in the consensus earnings data it aggregates for Arcutis Biotherapeutics.

Coverage

Newest first; wire copies grouped

Fri 00:00tickerreport.com